[PDF][PDF] Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia
JA De Lemos, CM de Oliveira, AC Scerni, AQ Bentes… - Genet Mol …, 2005 - academia.edu
Chronic myeloid leukemia (CML) originates from the hematopoietic stem cell and is
characterized by the reciprocal translocation t (9; 22)(q34; q11), which results in the BCR …
characterized by the reciprocal translocation t (9; 22)(q34; q11), which results in the BCR …
Antiproliferative effect in chronic myeloid leukaemia cells by antisense peptide nucleic acids
V Rapozzi, BEA Burm, S Cogoi… - Nucleic Acids …, 2002 - academic.oup.com
Peptide nucleic acid (PNA) is a synthetic DNA analogue that is resistant to nucleases and
proteases and binds with exceptional affinity to RNA. Because of these properties PNA has …
proteases and binds with exceptional affinity to RNA. Because of these properties PNA has …
C6‐Unsubstituted Pyrazolo[3,4‐d]pyrimidines Are Dual Src/Abl Inhibitors Effective against Imatinib Mesylate Resistant Chronic Myeloid Leukemia Cell Lines
MA Santucci, V Corradi, M Mancini… - ChemMedChem …, 2009 - Wiley Online Library
Docking simulations were used to predict the most favorable interaction between the T315I
mutated form of Abl (invariably associated with resistance to the tyrosine kinase inhibitor …
mutated form of Abl (invariably associated with resistance to the tyrosine kinase inhibitor …
Endoplasmic reticulum stress initiates apoptotic death induced by STI571 inhibition of p210 bcr–abl tyrosine kinase
L Pattacini, M Mancini, L Mazzacurati, G Brusa… - Leukemia research, 2004 - Elsevier
The endoplasmic reticulum (ER) is the site where proteins destined to either secretion or
different subcellular compartments assemble and the major storage of intracellular Ca2+ …
different subcellular compartments assemble and the major storage of intracellular Ca2+ …
P210 Bcr‐abl tyrosine kinase interaction with histone deacetylase 1 modifies histone H4 acetylation and chromatin structure of chronic myeloid leukaemia …
G Brusa, E Zuffa, M Mancini… - British journal of …, 2006 - Wiley Online Library
The BCR‐ABL fusion gene, originating from the balanced (9; 22) translocation, is the
molecular hallmark and the causative event of chronic myeloid leukaemia (CML). The …
molecular hallmark and the causative event of chronic myeloid leukaemia (CML). The …
尾静脉注射K562 细胞建立慢性髓系白血病小鼠模型及其鉴定
张佳， 杨文华， 杨向东， 史哲新， 王兴丽， 于文俊… - 中国实验血液学 …, 2012 - cqvip.com
本研究通过给NOD/SCID 小鼠尾静脉注射K562 细胞的方式, 建立人慢性髓系白血病(CML)-
NOD/SCID 小鼠髓外浸润模型, 并通过组织病理学检查及RT-PCR 检测BCR-ABL …
NOD/SCID 小鼠髓外浸润模型, 并通过组织病理学检查及RT-PCR 检测BCR-ABL …
Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606
M Mancini, G Brusa, E Zuffa, P Corrado, G Martinelli… - Leukemia research, 2007 - Elsevier
Complementary inhibition of tyrosine and SRC kinases implement dual SRC/ABL inhibitor
effects in chronic myeloid leukemia (CML). Here, we show that one such inhibitor, SKI-606 …
effects in chronic myeloid leukemia (CML). Here, we show that one such inhibitor, SKI-606 …
bcr/abl 基因表达的定量检测技术及临床意义
马晓霞， 王椿 - 白血病. 淋巴瘤, 2004 - cqvip.com
bcr/abl基因表达的定量检测技术及临床意义-[维普官方网站]-www.cqvip.com-维普网 我的维普
购物车 充值 客服 首页 | 期刊大全 | 文献分类 | 优先出版 | 论文检测 | 论文选题 | 在线分享 | 会议 …
购物车 充值 客服 首页 | 期刊大全 | 文献分类 | 优先出版 | 论文检测 | 论文选题 | 在线分享 | 会议 …
p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p (210) BCR-ABL tyrosine kinase
G Brusa, M Benvenuti, L Mazzacurati, M Mancini… - …, 2003 - haematologica.org
BACKGROUND AND OBJECTIVES: The p210 bcr-abl fusion protein has a key role in the
pathogenesis of chronic myeloid leukemia (CML). However, its influence on disease …
pathogenesis of chronic myeloid leukemia (CML). However, its influence on disease …
Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571.
L Mazzacurati, L Pattacini, G Brusa… - … Journal: the Official …, 2004 - europepmc.org
STI571 is the most innovative drug for the cure of Chronic Myeloid Leukemia. It inhibits, in
fact, the disease causative event, the p210 bcr-abl tyrosine kinase, and addresses clonal …
fact, the disease causative event, the p210 bcr-abl tyrosine kinase, and addresses clonal …